Search results for "Acute leukaemia"

showing 3 items of 3 documents

Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia

2019

Abstract The administration of cryopreserved platelets (PLTs) may overcome the limits of platelet shortage and availability, especially during some seasons or in specific contexts like rural areas. After in vitro validation studies, ad hoc prepared buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at -80 °C with a modified Valeri method, were transfused in patients with severe thrombocytopenia secondary to chemotherapy for acute leukaemia (AL). Five inpatients were enrolled in the pivotal clinical trial NCT02032134: 4 males and 1 female with a mean age of 71 years (range: 65–80). Four patients were diagnosed wi…

Blood PlateletsMalemedicine.medical_specialtymedicine.medical_treatmentPlatelet TransfusionBuffy coat030204 cardiovascular system & hematologyAcute leukaemiaCryopreservation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPlateletAdverse effectAgedAged 80 and overCryopreservationChemotherapybusiness.industryTransfusionThrombinSevere thrombocytopeniaThrombosisHematologyCryopreserved plateletThrombocytopeniaSevere thrombocytopeniaClinical trialLeukemia Myeloid AcuteBlood PreservationConcomitantBlood Buffy CoatFemaleSafetybusiness030215 immunologyTransfusion and Apheresis Science
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

2016

OncologyAcute promyelocytic leukemiaacute leukaemiamedicine.medical_specialtyacute promyelocytic leukaemiaPROTEÍNAS PROTO-ONCOGÊNICAS03 medical and health sciences0302 clinical medicineInternal medicinemedicineNeoplasmSurvival ratebusiness.industryFollow up studiesHematologymedicine.diseaseMinimal residual diseaseClinical trialLeukemiaPML/RARA; acute leukaemia; acute promyelocytic leukaemia; minimal residual disease; quantitative PCR030220 oncology & carcinogenesisquantitative PCRminimal residual diseaseAcute promyelocytic leukaemiabusinessPML/RARASettore MED/15 - Malattie del Sangue030215 immunology
researchProduct